https://www.medicaldaily.com/fda-approves-kadcyla-drug-seeks-out-and-destroys-breast-cancer-cells-244502
FDA Approves of Kadcyla, A Drug That Seeks Out And Destroys Breast Cancer Cells
Feb 22, 2013 - By combining an antibody that attaches to a commonly over-expressed receptor on breast cancer cells with a toxin, Kadcyla targets cancer cells and extends...
https://www.breastcancer.org/research-news/kadcyla-improves-survival-for-some-mets-dx
Kadcyla Improves Survival in Women Diagnosed With Metastatic, HER2-Positive Disease That's Stopped...
The TH3RESA study found that Kadcyla improved overall survival in women diagnosed with metastatic, HER2-positive breast cancer that had stopped responding to...
https://www.prnewswire.co.uk/news-releases/research-and-markets---global-antibody-drug-conjugates-adc-market-2017-2022-kadcyla-but-will-be-618482253.html
Research and Markets - Global Antibody Drug Conjugates (ADC) Market 2017-2022: Kadcyla but will be...
/PRNewswire/ -- Research and Markets has announced the addition of the "Global Antibody Drug Conjugates (ADC) Market - Analysis By Drugs (Adcetris, Kadcyla),...
https://www.healthdirect.gov.au/medicines/brand/amt,157721000036108/kadcyla
Kadcyla | healthdirect
On this page about Kadcyla you will find information relating to side effects, age restrictions, food interactions, whether the medicine is available at a...
kadcylahealthdirect
https://www.breastcancer.org/research-news/2-studies-confirm-kadcylas-benefits
Final Results From Two Studies Confirm Kadcyla's Benefits for Advanced-Stage HER2-Positive Disease
Final results from the EMILIA and TH3RESA studies show that Kadcyla improves overall survival in people diagnosed with advanced-stage HER2-positive breast...
https://www.roche.com/media/releases/med-cor-2019-02-05
Roche submits supplemental biologics license application to US FDA for Kadcyla for adjuvant...
Roche's application is being reviewed under the US FDA's Real-Time Oncology Review and Assessment Aid pilot programmes Kadcyla was granted Breakthrough Therapy...
biologics license application
https://www.roche.com/solutions/pharma/productid-64b71dad-d4bc-470a-8307-e56de10428ed
Roche | Kadcyla (trastuzumab emtansine)
rochekadcylatrastuzumabemtansine
https://www.fiercebiotech.com/keyword/kadcyla
Kadcyla | Fierce Biotech
kadcylafiercebiotech
https://www.breastcancer.org/research-news/kadcyla-better-survival-her2-positive-early-stage-breast-cancer
Study: Kadcyla Survival Benefits Last in HER2+ Breast Cancer
After eight years of follow-up, Kadcyla continued to improve overall and progression-free survival in people with early-stage, HER2-positive breast cancer.
last instudykadcylasurvivalbenefits
https://www.breastcancer.org/research-news/kadcyla-vs-herceptin-for-early-stage-her2-pos
Kadcyla Seems Better Than Herceptin for Early-Stage, HER2-Positive Residual Breast Cancer
For early-stage, HER2-Positive residual breast cancer, Kadcyla seems better than Herceptin
https://www.benzinga.com/general/biotech/21/08/22402550/astrazeneca-daiichi-sankyos-enhertu-shows-improved-pfs-over-roches-kadcyla-in-breast-cancer
AstraZeneca, Daiichi Sankyo's Enhertu Shows Improved PFS Over Roche's Kadcyla In Breast Cancer -...